{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Lyell Immunopharma, Inc. overvalued or undervalued?
As of February 29, 2024, Lyell Immunopharma, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a year-to-date decline of 29.77%, significantly underperforming compared to the S&P 500's 2.44% gain.
Is Lyell Immunopharma, Inc. technically bullish or bearish?
As of June 11, 2025, the technical trend has shifted to mildly bearish, driven by bearish signals from daily moving averages, Bollinger Bands, and the monthly KST, despite a mildly bullish weekly MACD.
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma, Inc. is a micro-cap biotechnology company with no recent net sales and a net loss of $52 million as of March 2025. It has a market cap of $143.64 million and key metrics indicating significant financial challenges, including a negative return on equity and no dividend yield.
How big is Lyell Immunopharma, Inc.?
As of Jun 18, Lyell Immunopharma, Inc. has a market capitalization of 143.64 million, with net sales of 0.06 million and a net profit of -334.53 million over the latest four quarters. Shareholder's funds are 382.82 million, and total assets are 490.86 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
